30 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Is a Beat in Store for Amarin (AMRN) This Earnings Season? http://www.zacks.com/stock/news/898431/is-a-beat-in-store-for-amarin-amrn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-898431 Apr 29, 2020 - Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Amgen (AMGN) Q1 Earnings Top, to Study Otezla for Coronavirus http://www.zacks.com/stock/news/910436/amgen-amgn-q1-earnings-top-to-study-otezla-for-coronavirus?cid=CS-ZC-FT-analyst_blog|earnings_article-910436 May 01, 2020 - Amgen (AMGN) beats estimates for both earnings and sales. It maintains its previously-issued financial guidance for 2020.
Biotech Industry Near-Term Outlook Modest Amid Coronavirus http://www.zacks.com/commentary/1048937/biotech-industry-near-term-outlook-modest-amid-coronavirus?cid=CS-ZC--industry_outlook-1048937 Aug 28, 2020 - Biotech Industry Near-Term Outlook Modest Amid Coronavirus
The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN http://www.zacks.com/stock/news/1055163/the-zacks-analyst-blog-highlights-moderna-sanofi-gsk-gild-and-amgn?cid=CS-ZC-FT-press_releases-1055163 Sep 08, 2020 - The Zacks Analyst Blog Highlights: Moderna, Sanofi, GSK, GILD and AMGN
J&J Seeks Label Expansion of Darzalex Faspro for Amyloidosis http://www.zacks.com/stock/news/1057271/jj-seeks-label-expansion-of-darzalex-faspro-for-amyloidosis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1057271 Sep 11, 2020 - J&J (JNJ) files sBLA to the FDA for expanding the label of Darzalex Faspro to treat patients with light chain amyloidosis. Currently, there are no approved therapies for the disease.
Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies http://www.zacks.com/stock/news/1060524/lilly-amgen-ink-manufacturing-deal-for-coronavirus-antibodies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1060524 Sep 18, 2020 - Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.
Powerful Proof Anyone Can Invest for an Early Retirement - April 01, 2020 http://www.zacks.com/stock/news/848812/powerful-proof-anyone-can-invest-for-an-early-retirement-april-01-2020?cid=CS-ZC-FT-retirement_ideas|secrets_to_an_early_retirement-848812 Apr 01, 2020 - Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Regeneron-Sanofi's Dupixent Data Positive in Atopic Dermatitis http://www.zacks.com/stock/news/857351/regeneron-sanofis-dupixent-data-positive-in-atopic-dermatitis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-857351 Apr 06, 2020 - Regeneron (REGN) and Sanofi announce positive detailed data on Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis.
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress http://www.zacks.com/stock/news/859545/biotech-stocks-etfs-to-gain-on-covid-19-vaccine-drug-progress?cid=CS-ZC-FT-etf_news_and_commentary-859545 Apr 07, 2020 - The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Will J&J's Pharma Unit Perform Above Market to Drive Q1 Result? http://www.zacks.com/stock/news/868906/will-jjs-pharma-unit-perform-above-market-to-drive-q1-result?cid=CS-ZC-FT-analyst_blog|earnings_preview-868906 Apr 13, 2020 - J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.

Pages: 123

<Page 2